Journal article
Increased intrahepatic apoptosis but reduced immune activation in HIV-HBV co-infected patients with advanced immunosuppression
DM Iser, A Avihingsanon, N Wisedopas, AJ Thompson, A Boyd, GV Matthews, SA Locarnini, J Slavin, PV Desmond, SR Lewin
AIDS | Published : 2011
Abstract
Objective: To determine if intrahepatic immune activation is increased in HIV-hepatitis B virus (HBV) co-infected patients compared to HBV mono-infected patients and whether this reduced following HBV-active antiretroviral therapy (ART) in HIV-HBV co-infected patients. Design: Case-control observational study. Methods: We examined liver biopsies for markers of T-cell and monocyte infiltration and activation, natural killer cells, hepatic stellate cell (HSC) activation (staining for alpha smooth muscle actin) and apoptosis [using terminal dUTP nick-end labelling (TUNEL)] in treatment-naive Asian HIV-HBV co-infected (n = 16) and HBV mono-infected patients matched for age and HBV e-antigen stat..
View full abstractGrants
Funding Acknowledgements
[ "The work was supported by the National Health and Medical Research Council (NHMRC) of Australia. S. R. L. is supported by an NHMRC Practitioner Fellowship. D. I. and A. T. are recipients of an NHMRC postgraduate scholarship. T.N. has received support from the Gastroenterological Society of Australia (GESA).", "Tenofovir in Co-infection (TICO) study was supported by Gilead Sciences. Clinical trial number NCT00192595.", "S.A.L. is a consultant for, advises, and received grants from, Evivar Pty Ltd and Gilead. He is a consultant for and owns stocks in Pharmasset, is a consultant for Bristol-Myers Squibb and has consulted for Abbott Laboratories. S. R. L. advises and has received grants from Gilead." ]